| Literature DB >> 30712844 |
Jinchul Kim1, Lili Yu2, Wancheng Chen2, Yanxia Xu2, Meng Wu2, Dilyana Todorova3, Qingshuang Tang2, Bingbing Feng2, Lei Jiang2, Jingjin He4, Guihua Chen4, Xuemei Fu5, Yang Xu6.
Abstract
The tumor suppressor p53 is somatically mutated in half of all human cancers. Paradoxically, the wild-type p53 (WTp53) is often retained in certain human cancers, such as hepatocarcinoma (HCC). We discovered a physiological and oncogenic role of WTp53 in suppressing pyruvate-driven oxidative phosphorylation by inducing PUMA. PUMA inhibits mitochondrial pyruvate uptake by disrupting the oligomerization and function of mitochondrial pyruvate carrier (MPC) through PUMA-MPC interaction, which depends on IκB kinase-mediated phosphorylation of PUMA at Ser96/106. High expression levels of PUMA are correlated with decreased mitochondrial pyruvate uptake and increased glycolysis in HCCs and poor prognosis of HCC patients. These findings are instrumental for cancer drug discovery aiming at activating WTp53 or restoring WTp53 activity to p53 mutants.Entities:
Keywords: PUMA; glycolysis; mitochondria; mitochondrial pyruvate carrier; oxidative phosphorylation; p53
Mesh：
Substances：
Year: 2019 PMID： 30712844 DOI： 10.1016/j.ccell.2018.12.012
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743